The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues

Journal of Medicinal Chemistry

Volumn 53, Issue 7, 2010, Pages 2843-2853

  Bergeron, Raymond J ^a   Bharti, Neelam ^a   Wiegand, Jan ^a   McManis, James S ^a   Singh, Shailendra ^a   Abboud, Khalil A ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6 DIOXAHEPTYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6,9 TRIOXATRIDECYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6,9,12 TETRAOXATRIDECYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; DEFERITRIN; DEFERRIFERRITHIOCIN; ETHYL 4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6 DIOXAHEPTYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; ETHYL 4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6,9,12 TETRAOXATRIDECYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; ISOPROPYL 4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6 DIOXAHEPTYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; IRON OVERLOAD; IRON THERAPY; MALE; NEPHROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIMATE; RAT; RODENT;

ANIMALS; BILE DUCTS; CEBUS; CRYSTALLOGRAPHY, X-RAY; DIHYDROPYRIDINES; DRUG DESIGN; ETHER, ETHYL; ETHERS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY; LIGANDS; MALE; OCTANOLS; PHYSICOCHEMICAL PROCESSES; RATS; THIAZOLES; WATER;

EID: 77950556593     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9018146     Document Type: Article

References (62)

1. Graf, E; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-Catalyzed Hydroxyl Radical Formation. Stringent Requirement for Free Iron Coordination Site J. Biol. Chem. 1984, 259, 3620 - 3624
2. Halliwell, B. Free Radicals and Antioxidants: A Personal View Nutr. Rev. 1994, 52, 253 - 265
3. Halliwell, B. Iron, Oxidative Damage, and Chelating Agents. In The Development of Iron Chelators for Clinical Use; Bergeron, R. J.; Brittenham, G. M., Eds.; CRC: Boca Raton, FL, 1994; pp 33 - 56.
4. Koppenol, W. Kinetics and Mechanism of the Fenton Reaction: Implications for Iron Toxicity. In Iron Chelators: New Development Strategies; Badman, D. G.; Bergeron, R. J.; Brittenham, G. M., Eds.; Saratoga: Ponte Vedra Beach, FL, 2000, pp 3 - 10.
5. Babbs, C. F. Oxygen Radicals in Ulcerative Colitis Free Radical Biol. Med. 1992, 13, 169 - 181
6. Hazen, S. L.; d'Avignon, A.; Anderson, M. M.; Hsu, F. F.; Heinecke, J. W. Human Neutrophils Employ the Myeloperoxidase-Hydrogen Peroxide-Chloride System to Oxidize α-Amino Acids to a Family of Reactive Aldehydes. Mechanistic Studies Identifying Labile Intermediates along the Reaction Pathway J. Biol. Chem. 1998, 273, 4997 - 5005
7. Millán, M; Sobrino, T.; Arenillas, J. F.; Rodriguez-Yáez, M.; Garca, M.; Nombela, F.; Castellanos, M.; de la Ossa, N. P.; Cuadras, P.; Serena, J.; Castillo, J.; Dávalos, A. Biological Signatures of Brain Damage Associated with High Serum Ferritin Levels in Patients with Acute Ischemic Stroke and Thrombolytic Treatment Dis. Markers 2008, 25, 181 - 188
8. Zecca, L.; Casella, L.; Albertini, A.; Bellei, C.; Zucca, F. A.; Engelen, M.; Zadlo, A.; Szewczyk, G.; Zareba, M.; Sarna, T. Neuromelanin Can Protect Against Iron-Mediated Oxidative Damage in System Modeling Iron Overload of Brain Aging and Parkinson's Disease J. Neurochem. 2008, 106, 1866 - 1875
9. Pietrangelo, A. Iron Chelation beyond Transfusion Iron Overload Am. J. Hematol. 2007, 82, 1142 - 1146
10. Pippard, M. J. Iron Overload and Iron Chelation Therapy in Thalassaemia and Sickle Cell Haemoglobinopathies Acta. Haematol. 1987, 78, 206 - 211
11. Olivieri, N. F. Progression of Iron Overload in Sickle Cell Disease Semin. Hematol. 2001, 38, 57 - 62
12. Malcovati, L. Impact of Transfusion Dependency and Secondary Iron Overload on the Survival of Patients with Myelodysplastic Syndromes Leukemia Res. 2007, 31, S2 - S6
13. Angelucci, E.; Brittenham, G. M.; McLaren, C. E.; Ripalti, M.; Baronciani, D.; Giardini, C.; Galimberti, M.; Polchi, P.; Lucarelli, G. Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major N. Engl. J. Med. 2000, 343, 327 - 331
14. Bonkovsky, H. L.; Lambrecht, R. W. Iron-Induced Liver Injury. Clin. Liver Dis. 2000, 4, 409 - 429, vi-vii.
15. Peitrangelo, A. Mechanism of Iron Toxicity Adv. Exp. Med. Biol. 2002, 509, 19 - 43
16. Cario, H.; Holl, R. W.; Debatin, K. M.; Kohne, E. Insulin Sensitivity and --Cell Secretion in Thalassemia Major with Secondary Haemochromatosis: Assessment by Oral Glucose Tolerance Test Eur. J. Pediatr. 2004, 162, 139 - 146
17. Wojcik, J. P.; Speechley, M. R.; Kertesz, A. E.; Chakrabarti, S.; Adams, P. C. Natural History of C282Y Homozygotes for Haemochromatosis Can. J. Gastroenterol. 2002, 16, 297 - 302
18. Brittenham, G. M. Disorders of Iron Metabolism: Iron Deficiency and Overload. In Hematology: Basic Principles and Practice, 3 rd ed.; Hoffman, R.; Benz, E. J.; Shattil, S. J.; Furie, B.; Cohen, H. J., Eds.; Churchill Livingstone: New York, 2000; pp 397 - 428.
19. Brittenham, G. M.; Griffith, P. M.; Nienhuis, A. W.; McLaren, C. E.; Young, N. S.; Tucker, E. E.; Allen, C. J.; Farrell, D. E.; Harris, J. W. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major N. Engl. J. Med. 1994, 331, 567 - 573
20. Zurlo, M. G.; De Stefano, P.; Borgna-Pignatti, C.; Di Palma, A.; Piga, A.; Melevendi, C.; Di Gregorio, F.; Burattini, M. G.; Terzoli, S. Survival and Causes of Death in Thalassemia Major Lancet 1989, 2, 27 - 30
21. Desferal; Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2008; http://www.pharma.us.novartis.com/product/pi/pdf/desferal.pdf.
22. Hoffbrand, A. V.; Al-Refaie, F.; Davis, B.; Siritanakatkul, N.; Jackson, B. F. A.; Cochrane, J.; Prescott, E.; Wonke, B. Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients Blood 1998, 91, 295 - 300
23. Olivieri, N. F. Long-Term Therapy with Deferiprone Acta Haematol. 1996, 95, 37 - 48
24. Olivieri, N. F.; Brittenham, G. M.; McLaren, C. E.; Templeton, D. M.; Cameron, R. G.; McClelland, R. A.; Burt, A. D.; Fleming, K. A. Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major N. Engl. J. Med. 1998, 339, 417 - 423
25. Richardson, D. R. The Controversial Role of Deferiprone in the Treatment of Thalassemia J. Lab. Clin. Med. 2001, 137, 324 - 329
26. Nisbet-Brown, E.; Olivieri, N. F.; Giardina, P. J.; Grady, R. W.; Neufeld, E. J.; Sechaud, R.; Krebs-Brown, A. J.; Anderson, J. R.; Alberti, D.; Sizer, K. C.; Nathan, D. G. Effectiveness and Safety of ICL670 in Iron-Loaded Patients with Thalassaemia: A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial Lancet 2003, 361, 1597 - 1602
27. Galanello, R.; Piga, A.; Alberti, D.; Rouan, M.-C.; Bigler, H.; Séchaud, R. Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to -Thalassemia J. Clin. Pharmacol. 2003, 43, 565 - 572
28. Cappellini, M. D. Iron-Chelating Therapy with the New Oral Agent ICL670 (Exjade) Best Pract. Res. Clin. Haematol. 2005, 18, 289 - 298
29. Exjade Prescribing Information; Novartis Pharmaceuticals Corporation: East Hanover, NJ, December, 2007; http://www.pharma.us.novartis.com/product/pi/ pdf/exjade.pdf.
30. Galanello, R.; Forni, G.; Jones, A.; Kelly, A.; Willemsen, A.; He, X.; Johnston, A.; Fuller, D.; Donovan, J.; Piga, A. A Dose Escalation Study of the Pharmacokinetics, Safety and Efficacy of Deferitrin, an Oral Iron Chelator in Beta Thalassaemia Patients ASH Annu. Meet. Abstr. 2007, 110, 2669
31. Pippard, M. J. Desferrioxamine-Induced Iron Excretion in Humans Bailliere's Clin. Haematol. 1989, 2, 323 - 343
32. Giardina, P. J.; Grady, R. W. Chelation Therapy in --Thalassemia: An Optimistic Update Semin. Hematol. 2001, 38, 360 - 366
33. Olivieri, N. F.; Brittenham, G. M. Iron-Chelating Therapy and the Treatment of Thalassemia Blood 1997, 89, 739 - 761
34. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Vinson, J. R. T.; Yao, H.; Bharti, N.; Rocca, J. R. (S)-4,5-Dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl- 4-thiazolecarboxylic Acid Polyethers: A Solution to Nephrotoxicity J. Med. Chem. 2006, 49, 2772 - 2783
35. Brittenham, G. M. Pyridoxal Isonicotinoyl Hydrazone. Effective Iron Chelation after Oral Administration Ann. N. Y. Acad. Sci. 1990, 612, 315 - 326
36. Naegeli, H.-U.; Zohner, H. Metabolites of Microorganisms. Part 193. Ferrithiocin Helv. Chim. Acta 1980, 63, 1400 - 1406
37. Hahn, F. E.; McMurry, T. J.; Hugi, A.; Raymond, K. N. Coordination Chemistry of Microbial Iron Transport. 42. Structural and Spectroscopic Characterization of Diastereomeric Cr(III) and Co(III) Complexes of Desferriferrithiocin J. Am. Chem. Soc. 1990, 112, 1854 - 1860
38. Anderegg, G.; Rober, M. Metal Complex Formation of a New Siderophore Desferrithiocin and of Three Related Ligands J. Chem. Soc., Chem. Commun. 1990, 1194 - 1196
39. Bergeron, R. J.; Wiegand, J.; Dionis, J. B.; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; Peter, H. H. Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators J. Med. Chem. 1991, 34, 2072 - 2078
40. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Vinson, J. R. T.; Luchetta, G.; Evans, K. M.; Peter, H.; Jenny, H.-B. A Comparative Evaluation of Iron Clearance Models Ann. N. Y. Acad. Sci. 1990, 612, 378 - 393
41. Bergeron, R. J.; Streiff, R. R.; Creary, E. A.; Daniels, R. D., Jr.; King, W.; Luchetta, G.; Wiegand, J.; Moerker, T.; Peter, H. H. A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model Blood 1993, 81, 2166 - 2173
42. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; McCosar, B. H.; Weimar, W. R.; Brittenham, G. M.; Smith, R. E. Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues J. Med. Chem. 1999, 42, 2432 - 2440
43. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bussenius, J.; Smith, R. E.; Weimar, W. R. Methoxylation of Desazadesferrithiocin Analogues: Enhanced Iron Clearing Efficiency J. Med. Chem. 2003, 46, 1470 - 1477
44. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; Vinson, J. R. T.; Bussenius, J.; Yao, G. W.; McManis, J. S. Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators J. Med. Chem. 1999, 42, 95 - 108
45. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bharti, N. The Design, Synthesis, and Evaluation of Organ-Specific Iron Chelators J. Med. Chem. 2006, 49, 7032 - 7043
46. Bergeron, R. J.; Wiegand, J.; Bharti, N.; Singh, S.; Rocca, J. R. Impact of the 3,6,9-Trioxadecyloxy Group on Desazadesferrithiocin Analogue Iron Clearance and Organ Distribution J. Med. Chem. 2007, 50, 3302 - 3313
47. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bharti, N.; Singh, S. Design, Synthesis, and Testing of Non-Nephrotoxic Desazadesferrithiocin Polyether Analogues J. Med. Chem. 2008, 51, 3913 - 3923
48. Bergeron, R. J.; Bharti, N.; Wiegand, J.; McManis, J. S.; Yao, H.; Prokai, L. Polyamine Vectored Iron Chelators: The Role of Charge J. Med. Chem. 2005, 48, 4120 - 4137
49. Brunner, H; Gruber, N. Carboplatin-Containing Porphyrin-Platinum Complexes as Cytotoxic and Phototoxic Antitumor Agents Inorg. Chim. Acta 2004, 357, 4423 - 4451
50. Kitto, H. J.; Schwartz, E.; Nijemeisland, M.; Koepf, M.; Cornelissen, J. J. L. M.; Rowan, A. E.; Nolte, R. J. M. Post-Modification of Helical Dipeptido Polyisocyanides Using the Click Reaction J. Mater. Chem. 2008, 18, 5615 - 5624
51. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; McManis, J. S.; Smith, R. E.; Abboud, K. A. Iron Chelation Promoted by Desazadesferrithiocin Analogues: An Enantioselective Barrier Chirality 2003, 15, 593 - 599
52. Sangster, J. Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry; John Wiley and Sons: West Sussex, England, 1997; Vol. 2.
53. White, G. P.; Jacobs, A.; Grady, R. W.; Cerami, A. The Effect of Chelating Agents on Iron Mobilization in Chang Cell Cultures Blood 1976, 48, 923 - 929
54. White, G. P.; Bailey-Wood, R.; Jacobs, A. The Effect of Chelating Agents on Cellular Iron Metabolism Clin. Sci. Mol. Med. 1976, 50, 145 - 52
55. Bergeron, R. J.; McManis, J. S.; Weimar, W. R.; Wiegand, J.; Eiler-McManis, E. Iron Chelators and Therapeutic Uses. In: Abraham, D. A., editor. Burger's Medicinal Chemistry, 6 th ed.; Wiley: New York: 2003; pp 479 - 561.
56. Torpac Rat and Guinea Pig Capsule and Accessory Pricing; Torpac: Fairfield, NJ; http://www.torpac.com/Torpac%20Rat%20Gpig%20Pricing.pdf.
57. SHELXTL6; Bruker-AXS: Madison, WI, 2000.
58. Bergeron, R. J.; Wiegand, J.; Ratliff-Thompson, K.; Weimar, W. R. The Origin of the Differences in (R)- and (S)-Desmethyldesferrithiocin: Iron-Clearing Properties Ann. N. Y. Acad. Sci. 1998, 850, 202 - 216
59. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Luchetta, G.; Creary, E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-one, 1,2-Diethyl-3-Hydroxypyrid-4-one, and Deferoxamine Blood 1992, 79, 1882 - 1890
60. Wood, J. K.; Milner, P. F.; Pathak, U. N. The Metabolism of Iron-Dextran Given As a Total-Dose Infusion to Iron Deficient Jamaican Subjects Br. J. Haematol. 1968, 14, 119 - 129
61. Bergeron, R. J.; Wiegand, J.; Brittenham, G. M. HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy Blood 1998, 91, 1446 - 1452
62. Bergeron, R. J.; Wiegand, J.; Wollenweber, M.; McManis, J. S.; Algee, S. E.; Ratliff-Thompson, K. Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators J. Med. Chem. 1996, 39, 1575 - 1581